[1] Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries. CA
Cancer J Clin. 2018;68:394-424.
[2] Rosendhal M, et al. Restaging and survival analysis of 4036 ovarian
cancer patients according to the 2013 FIGO classification for ovarian,
fallopian tube and primary peritoneal cancer. Int J Gynecol Cancer.
2016;26:680-687.
[3] LC Peres, et al. Invasive epithelial ovarian cancer survival by
histotype and disease stage. J Natl Cancer Inst. 2019;111:60-68.
[4] Stephanie L, et al. Epithelial Ovarian Cancer: Evolution of Management
in the Era of Precision Medicine. CA CANCER J CLIN. 2019;69:280–304.
[5] 榎本隆之. 日本産科婦人科学会婦人科腫瘍委員会報告. 第 59 回治療年報. 日産
婦誌 2018;70:1372-1444.
[6] 国立がん研究センターがん対策情報センター がん登録・統計. (2020)
http://gdb.ganjoho.jp/graph_db/
[7] 榎本隆之. 日本産科婦人科学会婦人科腫瘍委員会報告. 第 59 回治療年報. 日産
婦誌 2018;70:1372-1444.
[8] 卵巣がん・卵管癌・腹膜癌治療ガイドライン 2020 年版、金原出版
56
[9] 榎本隆之. 日本産科婦人科学会婦人科腫瘍委員会報告. 2017 年度患者年報. 日
産婦誌 2019;71:669-724.
[10] R. J. Kurman. Origin and molecular pathogenesis of ovarian high-grade
serous carcinoma. Annals of Oncology 24 (Supplement 10): x16–x21, 2013
doi:10.1093/annonc/mdt463.
[11] Labidi-Galy SI, et al. High grade serous ovarian carcinomas originate
in the fallopian tube. Nat Commun. 2017;8:1093.
[12] Lee, Y. et al. A candidate precursor to serous carcinoma that
originates in the distal fallopian tube. J. Pathol. 211, 26–35 (2007).
[13] Kindelberger DW, et al. Intraepithelial carcinoma of the fimbria and
pelvicserous carcinoma : evidence for a causal relationship. Am. J. Surg.
Pathol. 31,161–169 (2007).
[14] Cancer Genome Atlas Research Network. Integrated genomic analyses of
ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609-15.
doi:10.1038/nature10166.
[15] Ksenija N, et al. Targeting DNA repair: the genome as a potential
biomarker. J Pathol 2018; 244: 586–597.
57
[16] Walsh T, et al. Detection of inherited mutations for breast and
ovarian cancer using genomic capture and massively parallel sequencing.
Proc Natl Acad Sci U S A. 2010;107:12629-12633.
[17] Karoline B K, et al. Risks of Breast, Ovarian, and Contralateral
Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017 Jun
20;317(23):2402-2416.
doi: 10.1001/jama.2017.7112.
[18] Nasim M, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers:
results from prospective analysis of EMBRACE. Cancer Inst. 2013 Jun
5;105(11):812-22.
doi: 10.1093/jnci/djt095.
[19] Collins N, et al. Absence of methylation of CpG dinucleotides within
the promoter of the breast cancer susceptibility gene BRCA2 in normal
tissues and in breast and ovarian cancers. BrJ Cancer 1997; 76: 1150–1156.
[20] MS Piver, et al. Treatment of ovarian cancer at the crossroads: 50
years after single-agent melphalan chemotherapy. Oncology (Williston Park).
2006;20:1156,1158.
[21] Eric L, et al. The effect of maximal surgical cytoreduction on
sensitivity to platinum-taxane chemotherapy and subsequent survival in
patients with advanced ovarian cancer. Gynecologic Oncology 108 (2008) 276–
281
58
[22] Karam A, et al. Fifth Ovarian Cancer Consensus Conference of the
Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol.
2017;28:711-717.
[23] MK Wilson, D Aoki, et al. Fifth Ovarian Cancer Consensus Conference of
the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol.
2017;28:727-732.
[24] McGee J, et al. Fifth Ovarian Cancer Consensus Conference:
individualized therapy and patient factors. Ann Oncol. 2017;28:702-710.
[25] https://www.astrazeneca.co.jp/media/press-releases1/2020/20201228
02.html
[26] https://www.takeda.com/ja-jp/announcements/2020/parp2/
[27]
Jennine M.D, et al. PARP-1 Activation Requires Local Unfolding of an
Autoinhibitory Domain. Molecular Cell 60, 755–768, December 3, 2015.
[28] Levani Z, et al. Structural basis for allosteric PARP-1 retention
on DNA breaks. Science 368, eaax6367 (2020). DOI: 10.1126/science.aax6367.
[29] Junko M, et al. Trapping of PARP1 and PARP2 by Clinical PARP
Inhibitors. Cancer Res; 72(21) November 1, 2012.
[30] Michèle R, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer
10: 293–301 (2010). doi:10.1038/nrc2812.
59
[31] Thomas H. The underlying mechanism for the PARP and BRCA synthetic
lethality: Clearing up the misunderstandings. Molecular Oncology (2011)
387-393. doi:10.1016/j.molonc.2011.07.001.
[32] Helleday T, et al. DNA repair pathways as targets for cancer therapy.
Nature Rev Cancer. 2008;8:193-204.
[33] Murai J, et al. Trapping of PARP1 and PARP2 by clinical PARP
inhibitors. Cancer Res. 2012;72:5588-5599.
[34] Gelmon KA, et al. Olaparib in patients with recurrent high-grade
serous or poorly differentiated ovarian carcinoma or triple-negative breast
cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet
Oncol 2011;12:852-861. Available at: http://www.ncbi.nlm.nih.gov/pubmed/
21862407.
[35] Elit L, et al. Palliative systemic therapy for women with recurrent
epithelial ovarian cancer: current options. Onco Targets Ther 2013;6:107118. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23459506.
[36] Suh DH, et al. Major clinical research advances in gynecologic cancer
in 2014. J Gynecol Oncol 2015;26:156-167. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/25872896.
60
[37] Pujade-Lauraine E, et al. Olaparib tablets as maintenance therapy in
patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2
mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebocontrolled, phase 3 trial. Lancet Oncol 2017;18:1274-1284. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/28754483.
[38] Fong PC, et al. Poly(ADP)-ribose polymerase inhibition: frequent
durable responses in BRCA carrier ovarian cancer correlating with platinumfree interval. J Clin Oncol 2010;28:2512-2519. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/20406929.
[39] Ledermann J, et al. Olaparib maintenance therapy in platinum-sensitive
relapsed ovarian cancer. N Engl J Med 2012;366:1382-1392. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/22452356.
[40] National Comprehensive Cancer Network. NCCN clinical practice
guidelines in oncology: ovarian cancer version 1. 2020
(https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf).
[41] AstraZeneca. Lynparza (olaparib) tablets, for oral use: prescribing
information. 2018 (https://www.accessdata.fda.gov/drugsatfda _docs/label/
2018/208558s001lbl.pdf).
61
[42] MR Mirza, et al. Niraparib maintenance therapy in platinum-sensitive,
recurrent ovarian cancer. N Engl J Med 2016;375:2154-2164.
[43] MR Mirza, et al. Niraparib plus bevacizumab versus niraparib alone for
platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a
randomised, phase 2,superiority trial. Lancet Oncol 2019; 20: 1409–19
[44] Christoph P, et al. Mutations in regulators of the epigenome and their
connections to global chromatin patterns in cancer. Nat Rev Genet 14: 765–
780.doi:10.1038/nrg3554
[45] Stephen B, et al. A decade of exploring the cancer epigenome—
biological and translational implications. Nat Rev Cancer 11: 726–734.
doi:10.1038/nrc3130
[46] Jones P. A. & Baylin S. B. The fundamental role of epigenetic events
in cancer. Nature Rev. Genet. 3, 415–428 (2002).
[47] Jones P. A. & Baylin S. B. The epigenomics of cancer. Cell 128, 683–
692 (2007).
[48] Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148–1159
(2008).
62
[49] Y Saito, et al. Specific activation of microRNA‑127 with
downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in
human cancer cells. Cancer Cell 9, 435–443 (2006).
[50] Luger K, et al. Nucleosome and chromatin fiber dynamics. Curr Opin
Struct Biol 2005; 15: 188–196.
[51] B.D. Strahl, et al. The language of covalent histone modifications,
Nature 403 (2000) 41e45. https://doi.org/10.1038/47412.
[52] Greer EL & Shi Y. Histone methylation: a dynamic mark in health,
disease and inheritance. Nature Rev. Genet. 13, 343–357 (2012).
[53] Xi Zhang, et al. Emerging roles of lysine methylation on non-histone
proteins. Cell. Mol. Life Sci. (2015) 72:4257–4272. DOI 10.1007/s00018-0152001-4.
[54] Kyle K, et al. Non-histone protein methylation as a regulator of
cellular signalling and function. Nat Rev Mol Cell Bio 16: 5–17.
doi:10.1038/nrm3915.
[55] Black JC, et al. Histone lysine methylation dynamics: establishment,
regulation, and biological impact. Mol Cell 2012; 48: 491–507.
[56] Wagner EJ, et al. Understanding the language of Lys36 methylation at
histone H3. Nat Rev Mol Cell Biol 2012; 13: 115–126.
63
[57] Kwangbeom Hyun, et al. Writing, erasing and reading histone lysine
methylations. Exp & Mol Medi (2017) 49, e324; doi:10.1038/emm.2017.11.
[58] Paik WK, et al. Historical review: the field of protein methylation.
Trends Biochem. Sci. 32, 146–152 (2007).
[59] Kouzarides T. Histone methylation in transcriptional control. Curr
Opin Genet Dev (2002) 12(2):198–209 4.
[60] Zhou VW, et al. Charting histone modifications and the functional
organization of mammalian genomes. Nature Rev. Cancer 12, 7–18 (2011).
[61] Bannister AJ & Kouzarides T. Regulation of chromatin by histone
modifications. Cell Res. 21, 381–395 (2011)
[62] RJ Sims 3rd, et al. Histone lysine methylation: a signature for
chromatin function. Trends Genet (2003) 19(11):629–639 5.
[63] Martin C, et al. The diverse functions of histone lysine methylation.
Nat Rev Mol Cell Biol (2005) 6(11):838–849.
[64] Sabbattini P, et al. An H3K9/S10 methyl-phospho switch modulates
Polycomb and Pol II binding at repressed genes during differentiation. Mol.
Biol. Cell. 25, 904–915 (2014).
64
[65] Levy D. et al. Lysine methylation of the NF‑κB subunit RelA by SETD6
couples activity of the histone methyltransferase GLP at chromatin to tonic
repression of NF‑κB signaling. Nature Immunol. 12, 29–36 (2011).
[66] Xie Q, et al. Methylation-mediated regulation of E2F1 in DNA damageinduced cell death. J. Recept. Signal Transduct. Res. 31, 139–146 (2011).
[67] Botuyan MV, et al. Structural basis for the methylation state-specific
recognition of histone H4‑K20 by 53BP1 and Crb2 in DNA repair. Cell 127,
1361–1373 (2006).
[68] Dhayalan A, et al. Specificity analysis-based identification of new
methylation targets of the SET7/9 protein lysine methyltransferase. Chem.
Biol. 18, 111–120 (2011).
[69] Kwak YT, et al. Methylation of SPT5 regulates its interaction with RNA
polymerase II and transcriptional elongation properties. Mol. Cell 11,
1055–1066 (2003).
[70] Rho J, et al. Arginine methylation of Sam68 and SLM proteins
negatively regulates their poly(U) RNA binding activity. Arch. Biochem.
Biophys. 466, 49–57 (2007).
[71] Swiercz R, et al. Ribosomal protein rpS2 is hypomethylated in
PRMT3‑deficient mice. J. Biol. Chem. 282, 16917–16923 (2007).
65
[72] Carr SM, et al. Interplay between lysine methylation and Cdk
phosphorylation in growth control by the retinoblastoma protein. EMBO J.
30, 317–327 (2011).
[73] Martin G, et al. Arginine methylation in subunits of mammalian premRNA cleavage factor I. RNA 16, 1646–1659 (2010).
[74] Mazur PK, et al. SMYD3 links lysine methylation of MAP3K2 to Rasdriven cancer. Nature 510, 283–287 (2014).
[75] Lu R & Wang G, G Tudor. A versatile family of histone methylation
‘readers’. Trends Biochem. Sci. 38, 546–555 (2013).
[76] Gayatri S & Bedford MT. Readers of histone methylarginine marks.
Biochim. Biophys. Acta 1839, 702–710 (2014).
[77] Musselman CA, et al. Towards understanding methyllysine readout.
Biochim Biophys Acta 2014; 1839: 686–693.
[78] M Abu-Farha, et al. The tale of two domains: proteomics and genomics
analysis of SMYD2, a new histone methyltransferase. Mol Cell Proteomics,
2008, 7, 560–572.
[79] MA Brown, et al. Identification and characterization of Smyd2: a split
SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase
66
that interacts with the Sin3 histone deacetylase complex. Mol. Cancer 5
(2006) 26. https://doi.org/10.1186/1476-4598-5-26.
[80] Xu G, et al. The histone methyltransferase Smyd2 is a negative
regulator of macrophage activation by suppressing interleukin 6 (IL-6) and
tumor necrosis factor α (TNF-α) production. J. Biol. Chem. 290(9), 5414–
5423 (2015).
[81] J Huang, et al. Repression of p53 activity by Smyd2-mediated
methylation, Nature 444 (2006) 629e632. https://doi.org/10.1038/nature
05287.
[82] HS Cho, et al. RB1 methylation by SMYD2 enhances cell cycle
progression through an increase of RB1 phosphorylation. Neoplasia, 14,
2012, 476e486. https://doi.org/10.1593/neo.12656.
[83] L Piao, et al. The histone methyltransferase SMYD2 methylates PARP1
and promotes poly(ADP-ribosyl)ation activity in cancer cells, Neoplasia 16
(2014) 257e264. https://doi.org/10.1016/j.neo.2014.03.002.
[84] R Hamamoto, et al. SMYD2-dependent HSP90 methylation promotes cancer
cell proliferation by regulating the chaperone complex formation, Cancer
Lett. 351 (2014) 126e133. https://doi.org/10.1016/j.canlet.2014.05.014.
67
[85] X Zhang, et al. Regulation of estrogen receptor α by histone
methyltransferase SMYD2‑mediated protein methylation. Proc. Natl Acad. Sci.
USA 110,17284–17289 (2013).
[86] R Wang, et al. Effects of SMYD2-mediated EML4-ALK methylation on the
signaling pathway and growth in non-small-cell lung cancer cells. Cancer
Sci. 108 (2017) 1203e1209. https://doi.org/10.1111/cas.13245.
[87]
Xiaolan D, et al. Critical roles of SMYD2-mediated b-catenin
methylation for nuclear translocation and activation of Wnt signaling.
Oncotarget 8 (2017) 55837e55847, https://doi.org/10.18632/oncotarget.19646.
[88] M Nakakido, et al. Dysregulation of AKT pathway by SMYD2-mediated
lysine methylation on PTEN, Neoplasia 17 (2015) 367e373.
https://doi.org/10.1016/j.neo.2015.03.002.
[89] N Reynoird, et al. Coordination of stress signals by the lysine
methyltransferase SMYD2 promotes pancreatic cancer. Genes Dev. 2016 Apr
1;30(7):772-85.
doi: 10.1101/gad.275529.115.
[90] LX Li, et al. Lysine methyltransferase SMYD2 promotes triple negative
breast cancer progression, Cell Death Dis. 9 (2018). https://doi.org/10.
1038/s41419-018-0347-x.
68
[91] Hannah N, et al. LLY-507, a Cell-active, Potent, and Selective
Inhibitor of Protein-lysine Methyltransferase SMYD2. THE JOURNAL OF
BIOLOGICAL CHEMISTRY VOL.290, NO.22, pp. 13641–13653, May 29, 2015.
[92] Yi Z, et al. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation
Is Implicated in Tumorigenesis. Cell Reports 29, 1482–1498, November 5,
2019. https://doi.org/10.1016/j.celrep.2019.10.004.
[93] Fanchao M, et al. SMYD2 suppresses APC2 expression to activate the
Wnt/β-catenin pathway and promotes epithelial-mesenchymal transition in
colorectal cancer.
[94] Chen, A. PARP inhibitors: its role in treatment of cancer. Chin. J.
Cancer 30, 463–471 (2011).
[95] R Hamamoto, et al. Critical roles of non-histone protein lysine
methylation in human tumorigenesis, Nat Publ. Gr. 15 (2015) 110-124.
https://doi.org/10.1038/nrc3884.
[96] L Yan, et al. Inhibition of SMYD2 suppresses tumor progression by
down-regulating microRNA-125b and attenuates multi-drug resistance in renal
cell carcinoma. Theranostics.2019,Oct,22;9(26):8377-8391. doi:10.7150/thno.
37628.
69
[97] M Kojima, et al. The histone methyltransferase SMYD2 is a novel
therapeutic target for the induction of apoptosis in ovarian clear cell
carcinoma cells. Oncol Lett. 2020 Nov;20(5):153.
doi: 10.3892/ol.2020.
12014.
[98] JJ Sun, et al. SMYD2 promotes cervical cancer growth by stimulating
cell proliferation. Cell Biosci. 2019 Sep 18;9:75. doi:10.1186/s13578-0190340-9.
[99] S Komatsu, et al. Overexpression of SMYD2 relates to tumor cell
proliferation and malignant outcome of esophageal squamous cell carcinoma.
Carcinogenesis 30, 1139–1146 (2009).
[100] S Komatsu, et al. Overexpression of SMYD2 contributes to malignant
outcome in gastric cancer. Br. J. Canc. 112 (2015)357-364.
https://doi.org/10.1038/bjc.2014.543.
[101] LHT Sakamoto, et al. SMYD2 is highly expressed in pediatric acute
lymphoblastic leukemia and constitutes a bad prognostic factor. Leuk Res.
2014 Apr;38(4):496-502.
doi: 10.1016/j.leukres.2014.01.013.
[102] Shan-Ru Z, et al. Positive Expression of SMYD2 is Associated with
Poor Prognosis in Patients with Primary Hepatocellular Carcinoma. 2018;
9(2): 321-330. doi: 10.7150/jca.22218.
70
[103] S Ooki, et al. Oncogenic histone methyltransferase EZH2: a novel
prognostic marker with therapeutic potential in endometrial cancer,
Oncotarget 8 (2017) 40402e40411, https://doi.org/10.18632/oncotarget.16316.
[104] T Fukuda, et al. The anti-malarial chloroquine suppresses
proliferation and overcomes cisplatin resistance of endometrial cancer
cells via autophagy inhibition, Gynecol. Oncol. 137 (2015) 538e545.
https://doi.org/10.1016/j.ygyno.2015.03.053.
[105] Y Li, et al. Elevated expression of CXC chemokines in pediatric
osteosarcoma patients, Cancer 117 (2011) 207e217, https://doi.org/10.1002/
cncr.25563.
[106] SH Jang, et al. High EZH2 protein expression is associated with poor
overall survival in patients with luminal a breast cancer, J B
Can19(2016)53e60. https://doi.org/10.4048/jbc.2016.19.1.53.
[107] A Vaidyanathan, et al. ABCB1 (MDR1) induction defines a common
resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer
cellsBr J Cancer. 2016 Aug 9;115(4):431-41.
doi: 10.1038/bjc.2016.203.
[108] Peralta-Leal A, et al. Poly(ADP-ribose) polymerase-1 (PARP-1) in
carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clin
Transl Oncol 10, 318–323 (2008).
71
...
論文の公開元へ
